Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free ...

The targeting of telomeres offers promise for new cancer therapies, which can be aimed at disrupting the mechanisms that ...

LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for ...

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ ...

With better risk stratification, clinicians may be able to optimize medical management of patients with chronic HBV who don’t ...

1Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. 2Clinical Research Center for Colorectal Cancer in Heilongjiang, Harbin, China. 3Key ...

Commissions do not affect our editors' opinions or evaluations. If you’ve been diagnosed with cancer and do not already have a policy in place, you will find your life insurance options much mor ...

Fintel reports that on January 8, 2025, Stifel initiated coverage of Altimmune (NasdaqGM:ALT) with a Buy recommendation ... developing intranasal vaccines, immune modulating therapies and ...

On Tuesday, Stifel analysts initiated coverage on Altimmune (NASDAQ:ALT) shares, traded on NASDAQ: ALT, with a Buy rating and set a price target of $18.00. The firm’s analysts point to the company’s ...

On Tuesday, Stifel analysts initiated coverage on Altimmune (NASDAQ:ALT) shares, traded on NASDAQ: ALT, with a Buy rating and set a price target of $18.00. The firm's analysts point to the company ...